Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.

Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N.

Eur J Cancer. 2019 Jan 12;108:88-96. doi: 10.1016/j.ejca.2018.12.017. [Epub ahead of print]

PMID:
30648633
2.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
3.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino M.

Ann Oncol. 2019 Jan 8. doi: 10.1093/annonc/mdy553. [Epub ahead of print] No abstract available.

PMID:
30624547
4.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY.

Ann Oncol. 2018 Dec 28. doi: 10.1093/annonc/mdy554. [Epub ahead of print]

PMID:
30596843
5.

Safety of osimertinib in EGFR-mutated non-small cell lung cancer.

Mezquita L, Varga A, Planchard D.

Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248. doi: 10.1080/14740338.2018.1549222. Epub 2018 Dec 5. Review.

PMID:
30457891
6.

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.

Schernberg A, Mezquita L, Boros A, Botticella A, Caramella C, Besse B, Escande A, Planchard D, Le Péchoux C, Deutsch E.

PLoS One. 2018 Oct 10;13(10):e0204490. doi: 10.1371/journal.pone.0204490. eCollection 2018.

7.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available.

8.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
9.

Have We Really MET a New Target?

Planchard D.

J Clin Oncol. 2018 Sep 25:JCO2018793455. doi: 10.1200/JCO.2018.79.3455. [Epub ahead of print] No abstract available.

PMID:
30252573
10.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Yu HA, Planchard D, Lovly CM.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):726-739. doi: 10.1200/EDBK_201331. Review.

PMID:
30231382
11.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

PMID:
30193240
12.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
13.

Durvalumab for the treatment of non-small cell lung cancer.

Mezquita L, Planchard D.

Expert Rev Respir Med. 2018 Aug;12(8):627-639. doi: 10.1080/17476348.2018.1494575. Epub 2018 Jul 9.

PMID:
29958099
14.

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Geraud A, Mezquita L, Bigot F, Caramella C, Planchard D, Le Pechoux C, Besse B.

J Thorac Oncol. 2018 Nov;13(11):e215-e217. doi: 10.1016/j.jtho.2018.05.033. Epub 2018 Jun 6. No abstract available.

PMID:
29885478
15.

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D.

Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29729495
16.

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Planchard D, Johnson BE.

Arch Pathol Lab Med. 2018 Jul;142(7):796-797. doi: 10.5858/arpa.2018-0088-ED. Epub 2018 Apr 12. No abstract available.

PMID:
29648886
17.

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Mezquita L, Planchard D.

Cancer Manag Res. 2018 Jan 18;10:123-130. doi: 10.2147/CMAR.S129963. eCollection 2018. Review.

18.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
19.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

20.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B.

Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7.

PMID:
29191602
21.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
22.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
23.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

24.

Durvalumab in non-small-cell lung cancer patients: current developments.

Mezquita L, Planchard D.

Future Oncol. 2018 Feb;14(3):205-222. doi: 10.2217/fon-2017-0373. Epub 2017 Nov 15. Review.

PMID:
29140105
25.

AZD3759 for CNS metastases in EGFR-mutant lung cancer.

Planchard D.

Lancet Respir Med. 2017 Nov;5(11):841-842. doi: 10.1016/S2213-2600(17)30395-8. Epub 2017 Oct 19. No abstract available.

PMID:
29056569
26.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
27.

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N.

J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081.

PMID:
28967957
28.

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.

PMID:
28919011
29.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.

30.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

31.

Are we reproducible in measurement of NET liver metastasis?

Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E.

Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.

PMID:
28844707
32.

Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.

Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R, Grimaldi F, Pizzolitto S, Guigay J, de Latour BR, Giuffrida D, Longchampt E, de Montpreville VT, Fadel E, Colao A, Planchard D, Papotti M, Faggiano A, Baudin E.

Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.

PMID:
28813709
33.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

PMID:
28798088
34.

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.

PMID:
28633480
35.

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

Atlan P, Bayar MA, Lanoy E, Besse B, Planchard D, Ramon J, Raynard B, Antoun S.

Support Care Cancer. 2017 Nov;25(11):3365-3373. doi: 10.1007/s00520-017-3755-z. Epub 2017 Jun 8.

PMID:
28593463
36.

Targeting ALK-rearranged non-small-cell lung cancer: an update.

Sullivan I, Planchard D.

Future Oncol. 2017 Jun;13(14):1213-1217. doi: 10.2217/fon-2017-0127. Epub 2017 Jun 7. No abstract available.

PMID:
28589737
37.

Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.

Planchard D, Remon J, Nowak F, Soria JC.

Am Soc Clin Oncol Educ Book. 2017;37:12-17. doi: 10.14694/EDBK_100007. Review. No abstract available.

38.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.

39.

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.

Boros A, Lacroix L, Lacas B, Adam J, Pignon JP, Caramella C, Planchard D, de Montpreville V, Deutsch E, Levy A, Besse B, Le Pechoux C.

Oncotarget. 2017 Apr 11;8(15):25189-25199. doi: 10.18632/oncotarget.15966.

40.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.

PMID:
28242503
41.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA.

J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.

42.

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.

Sullivan I, Planchard D.

Front Med (Lausanne). 2017 Jan 18;3:76. doi: 10.3389/fmed.2016.00076. eCollection 2016. Review.

43.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.

PMID:
28104619
45.

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O.

Invest New Drugs. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12.

PMID:
27838867
46.

A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.

Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM.

Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11.

47.

Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.

Facchinetti F, Caramella C, Auger N, Planchard D, Adam J, Lacroix L, Remon J, Massard C, Soria JC, Friboulet L, Besse B.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000520.

PMID:
27197808
49.

Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.

Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B.

Lung Cancer. 2016 Sep;99:111-6. doi: 10.1016/j.lungcan.2016.06.020. Epub 2016 Jul 1.

PMID:
27565923
50.

Reply to N. Singh et al.

Planchard D.

J Clin Oncol. 2016 Nov 20;34(33):4055-4056. doi: 10.1200/JCO.2016.68.9349. Epub 2016 Oct 31. No abstract available.

PMID:
27551135

Supplemental Content

Loading ...
Support Center